The Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI): description and evaluation of an innovative pediatric, adolescent, and young adult antiretroviral service delivery model in Tanzania

• Published in: BMC infectious diseases 2018-09, Vol.18 (1), p.448-448, Article 448
• Main Authors: Bacha, Jason M, Aririguzo, Lynda C, Mng'ong'o, Veronica, Malingoti, Beatrice, Wanless, Richard S, Ngo, Katherine, Campbell, Liane R, Schutze, Gordon E
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adolescents; Adults; AIDS; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; ART delivery; Children; Complications; Diagnosis; Differentiated models of care; Dosage and administration; Drug therapy; Drugs; Evaluation; Expedited encounters; HIV; Human immunodeficiency virus; Immunodeficiency; Lost to follow up; Medical innovations; Mortality; Patients; Pediatric HIV infections; Pediatric HIV/AIDS; Practice guidelines (Medicine); Teenagers; Young adults
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-018-3331-2

As countries scale up antiretroviral therapy (ART) for children, innovative strategies to deliver quality services to children are needed. Differentiated ART delivery models have been successful in adults, but no such program has been described in children. We describe the Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI). Descriptive analysis of patients eligible for SPEEDI was done via retrospective review of children, adolescents, and young adults on ART at the Baylor Centre of Excellence (COE) in Mbeya, Tanzania between January 2013 and December 2015. Eligibility for SPEEDI visits included the following: stable children, adolescents, and young adults on ART for approximately 3 months or longer, no medical or social complications, good adherence to ART, and presence of reliable caregiver. During a SPEEDI visit, patients were fast tracked in triage to collect medications directly without physically seeing a clinician. SPEEDI patients came to clinic every two months, and alternated SPEEDI visits with standard visits. Baseline characteristics, mortality, and lost-to-follow up rates of SPEEDI patients were analyzed. One thousand one hundred sixty-four patients utilized SPEEDI, totaling 3493 SPEEDI visits. SPEEDI reached 51.3% (1164/2269) of pediatric ART patients, accounting for 7.7% (3493/44489) of total patient encounters. SPEEDI patients were 52% (605/1164) female, median age of 11.7 years (range 1.2-25.5 yr), median time on ART of 21 months (range 4-130 months) and 83.5% (964/1155) categorized as no or mild HIV-associated immunodeficiency. SPEEDI patients had good outcomes (98.8%), low LTFU (0.1%) and low mortality rates (0.61 deaths per 100 patient-years). SPEEDI was an effective model for delivering ART to children, adolescents, and young adults in our setting, leading to good clinical outcomes, low mortality, and low LTFU. The SPEEDI program safely and effectively expedited and spaced out ART visits for children, adolescents, and young adults, and can serve as an adaptable ART delivery model for other resource limited settings.